G9645 – Patients who did not abstain from smoking prior to anesthesia on the day of surgery or procedure

Long description

Patients who did not abstain from smoking prior to anesthesia on the day of surgery or procedure

Short description

Had smoke b/4 anes day surg

Pricing indicator

00 Not separately priced by Part B (bundled, not covered or Part A only)

Medicare coverage

C Carrier judgment – coverage decided by the Medicare contractor

BETOS category

Z2 Undefined codes

Added

January 1, 2016

Last change

January 1, 2016 – No change

Nearby G codes

• G9637 – Final reports with documentation of one or more dose reduction techniques (e.g., automated exposure control, adjustment of the ma and/or kv according to patient size, use of iterative reconstruction technique)
• G9638 – Final reports without documentation of one or more dose reduction techniques (e.g., automated exposure control, adjustment of the ma and/or kv according to patient size, use of iterative reconstruction technique)
• G9639 – Major amputation or open surgical bypass not required within 48 hours of the index endovascular lower extremity revascularization procedure
• G9640 – Documentation of planned hybrid or staged procedure
• G9641 – Major amputation or open surgical bypass required within 48 hours of the index endovascular lower extremity revascularization procedure
• G9642 – Current smoker (e.g., cigarette, cigar, pipe, e-cigarette or marijuana)
• G9643 – Elective surgery
• G9644 – Patients who abstained from smoking prior to anesthesia on the day of surgery or procedure
• G9646 – Patients with 90 day mrs score of 0 to 2
• G9647 – Patients in whom mrs score could not be obtained at 90 day follow-up
• G9648 – Patients with 90 day mrs score greater than 2
• G9649 – Psoriasis assessment tool documented meeting any one of the specified benchmarks (e.g., (pga; 5-point or 6-point scale), body surface area (bsa), psoriasis area and severity index (pasi) and/or dermatology life quality index) (dlqi))
• G9650 – Documentation that the patient declined therapy change or has documented contraindications (e.g., experienced adverse effects or lack of efficacy with all other therapy options) in order to achieve better disease control as measured by pga, bsa, pasi, or dlqi
• G9651 – Psoriasis assessment tool documented not meeting any one of the specified benchmarks (e.g., (pga; 5-point or 6-point scale), body surface area (bsa), psoriasis area and severity index (pasi) and/or dermatology life quality index) (dlqi)) or psoriasis assessment tool not documented
• G9652 – Patient has been treated with a systemic or biologic medication for psoriasis for at least six months
• G9653 – Patient has not been treated with a systemic or biologic medication for psoriasis for at least six months